RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
Study of Erlotinib in Patients with Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAS1430
U.S. Govt. ID: NCT02193282
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to look at the effects of treating Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer with the standard treatment or standard treatment in addition to Erlotinib. Subjects will be randomized to one of the two study groups. Subjects will be on the study for up to two years.
This study is closed
Investigator
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with EGFR mutated non-small cell lung cancer? Yes No
Have you undergone complete surgical resection of your stage IB, II, or IIIA NSCLC? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE